Researchers have identified specific molecular changes in the brains of aging rhesus macaques following chronic treatment with a glutamate carboxypeptidase II inhibitor, offering new insights into potential therapeutic strategies for sporadic Alzheimer’s disease. The study, published in Acta Neuropathologica Communications, utilized region-specific proteomic analysis to examine how this intervention affects vulnerable and resilient areas of the primate cortex. By mapping these proteomic shifts, the team revealed molecular signatures that may serve as candidate biomarkers and highlighted novel mechanistic pathways contributing to calcium-driven neurodegeneration in the disease.
Sporadic Alzheimer’s disease currently lacks effective preventive therapies, which underscores the urgent need to target underlying pathogenic drivers. Aberrant calcium signaling is an established early event in the pathogenesis of the condition and is closely linked to neuroinflammation. Aged rhesus macaques are predominantly APOE-ε4 homozygotes and naturally exhibit cognitive decline, calcium dysregulation, amyloid deposition, and tau pathology.
The research builds on prior work that identified an evolutionarily expanded role for postsynaptic type 3 metabotropic glutamate receptors in the dorsolateral prefrontal and entorhinal cortex. In these regions, these receptors regulate the opening of potassium channels via cAMP and calcium signaling, a process essential for sustaining neuronal firing and working memory. The signaling of these receptors is driven by N-acetylaspartylglutamate and constrained by glutamate carboxypeptidase II, an enzyme whose expression rises with age and inflammation. Previous studies demonstrated that chronic inhibition of this enzyme with the orally bioavailable inhibitor 2-(3-mercaptopropyl) pentanedioic acid improved neuronal firing and working memory while reducing tau pathology in aged macaques.
To define the broader proteomic consequences of this treatment, the current study employed liquid chromatography tandem mass spectrometry. The researchers analyzed brain tissue from vulnerable regions, specifically the entorhinal cortex and dorsolateral prefrontal cortex, and compared them with resilient regions, such as the primary visual cortex. This comparative approach allowed the team to identify region-specific differential expression patterns that paralleled known vulnerability gradients in sporadic Alzheimer’s disease. The study identified more than 2,400 proteins across the experimental conditions, providing a comprehensive map of the molecular landscape affected by the inhibitor.
Label-free quantification revealed distinct patterns of protein expression that varied by brain region. A number of these proteomic hits were further validated using Western blot analysis to ensure the reliability of the mass spectrometry data. Gene ontology enrichment analysis of the vulnerable regions implicated several key biological pathways, including those governing protein deneddylation, amyloid and tau-associated processes, synaptic plasticity, mitochondrial homeostasis, and oxidative stress. These pathways represent putative targets for therapeutic intervention, suggesting that the inhibitor engages distinct, region-selective molecular programs in the aging primate cortex.
The findings are consistent with the protection of neural circuits that are most vulnerable to sporadic Alzheimer’s disease. The study suggests that targeting glutamate carboxypeptidase II may help preserve the function of specific cortical areas that are typically affected early in the disease process.
The authors note that more focused investigations into these pathways of therapeutic interest are warranted. Additionally, the analysis of key post-translational modifications and their potential roles in sporadic Alzheimer’s disease is necessary to fully understand the mechanisms at play. While the current study provides a detailed proteomic profile, it does not directly prove clinical efficacy in humans. However, the use of a translationally relevant animal model and the identification of specific molecular targets offer a strong foundation for future research.
The identification of specific proteins and pathways affected by glutamate carboxypeptidase II inhibition provides a roadmap for further investigation.
Subject of Research: Region-specific proteomic effects of chronic GCPII inhibition in aging rhesus macaques
Article Title: Region-specific proteomic analysis of aging rhesus macaques following chronic glutamate-carboxypeptidase-II (GCPII) inhibition elucidates potential treatment strategies for sporadic Alzheimer’s disease
Article References: Steigmeyer, A. D., Battison, A. S., Liebman, I. R., van Dyck, C. H., Slusher, B. S., Arnsten, A. F. T., Malaker, S. A., & Datta, D. (2026). Region-specific proteomic analysis of aging rhesus macaques following chronic glutamate-carboxypeptidase-II (GCPII) inhibition elucidates potential treatment strategies for sporadic Alzheimer’s disease. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-026-02442-4
Image Credits: AI Generated
DOI: 10.1186/s40478-026-02442-4
Keywords: Alzheimer’s disease, Proteomics, Rhesus macaques, GCPII inhibition, Neurodegeneration, Calcium signaling, Brain regions, Biomarkers, Neuroinflammation, Tau pathology, Region-specific, proteomic
